NCT00064649

Minimally Invasive Surgical Therapy for BPH

Minimally Invasive Surgical Therapy Consortium for Benign Prostatic Hyperplasia

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 49 (actual)
• Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · NIH
• Sex: Male
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of this randomized clinical trial is to determine the efficacy and safety of three treatments for benign prostatic hyperplasia (BPH): transurethral needle ablation (TUNA), transurethral microwave therapy (TUMT), and medical therapy with alfuzosin and finasteride.

Conditions

• Benign Prostatic Hyperplasia

Interventions

Type	Name	Description
DEVICE	Transurethral Microwave Thermotherapy (TUMT)	type of minimally invasive surgical therapy for BPH
DEVICE	Transurethral Needle Ablation (TUNA) Therapy	type of minimally invasive surgical therapy for BPH
DRUG	Finasteride and Alfuzosin	finasteride in a daily dose of 5 mg and alfuzosin in a daily dose of 10 mg

Timeline

• Start date: 2004-04-01
• Completion: 2006-06-01
• First posted: 2003-07-11
• Last updated: 2010-01-14

Locations

7 sites across 1 country: United States